Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

European urology·2026

Same author

Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences.

Brachytherapy·2025

Same author

Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life.

JAMA network open·2024

Same author

Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center.

Clinical and translational radiation oncology·2024

Same author

Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry.

Brachytherapy·2023

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model

Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model

Published on: May 27, 2016

Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model.

Susan L Tucker¹, Lei Dong, Walter R Bosch

¹Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1402, USA. sltucker@mdanderson.org

International Journal of Radiation Oncology, Biology, Physics

|July 6, 2010

Summary

This study estimates parameters for the Lyman normal-tissue complication probability model using rectal toxicity data from prostate cancer radiotherapy patients. The model helps predict long-term risks of Grade ≥2 late rectal toxicity.

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Published on: September 11, 2012

Related Experiment Videos

Last Updated: Jun 11, 2026

Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model

Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model

Published on: May 27, 2016

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Published on: September 11, 2012

Area of Science:

Radiation oncology
Clinical trial analysis
Biostatistics

Background:

Prostate cancer radiotherapy, specifically three-dimensional conformal radiotherapy (3D-CRT), aims to maximize tumor control while minimizing normal tissue complications.
Late rectal toxicity is a significant concern following prostate cancer treatment, impacting patient quality of life.
Accurate modeling of normal tissue complication probability (NTCP) is crucial for optimizing radiation therapy planning and dose prescription.

Purpose of the Study:

To estimate the parameters of the Lyman-Kutcher-Burman (LKB) normal-tissue complication probability (NTCP) model.
To assess Grade ≥2 late rectal toxicity in patients treated with 3D-CRT for prostate cancer.
To utilize censored time-to-event data from the Radiation Therapy Oncology Group (RTOG) 94-06 trial.

Main Methods:

Fitted the Lyman NTCP model to data from 1,010 patients from the RTOG 94-06 trial.
Employed an approach accounting for censored observations in time-to-event analysis.
Performed separate analyses using dose-volume histograms (DVH) for the whole rectum and dose-wall histograms (DWH) for the rectal wall.

Main Results:

The crude incidence of Grade ≥2 late rectal toxicity was 15% after a median follow-up of 7.2 years.
Lyman model parameters (TD50, m, n) were estimated using DVH data, providing insights into rectal complication risk.
Cardiovascular disease was significantly associated with higher rectal toxicity incidence (p=0.015), unlike other comorbidities or treatment variables.

Conclusions:

The estimated Lyman model parameters are representative of long-term Grade ≥2 late rectal toxicity risk after 3D-CRT for prostate cancer.
The findings support the utility of the Lyman model in predicting rectal toxicity in this patient population.
The study highlights the importance of considering patient comorbidities, such as cardiovascular disease, in toxicity risk assessment.